Investors should consider Hims & Hers Health (HIMS) as a high-conviction play while it trades near $19, representing a significant disconnect from its strong fundamental growth. The company’s shift toward branded Novo Nordisk (NVO) GLP-1s and its avoidance of patent-infringing compounds may pave the way for a lucrative future partnership with Eli Lilly (LLY). With 95% recurring revenue and a recession-proof subscription model, HIMS is positioned as a core long-term holding for the 2030s. The recent acquisition of a peptide manufacturing facility provides a massive competitive moat, allowing the company to control its supply chain as the Peptide market expands. Ignore short-term macro volatility and focus on this transition from a telehealth provider to a vertically integrated personalized medicine powerhouse.

Hims & Hers Health, Inc. (HIMS)

• The stock is currently trading around $19, which the analyst believes is a disconnect from the company's strong fundamental performance. • Market Sentiment vs. Reality: The analyst argues that HIMS is currently trading based on "macro madness" (Middle East tensions, oil prices, and general market liquidity) rather than its own business developments. • Recession-Proof Business Model: * The company operates on a 95% recurring revenue model. * Subscriptions range from $50 to $80 a month, which is often cheaper than traditional insurance co-pays and doctor visit fees ($200+). * Products (ED, hair loss, weight loss) are considered "essential" and "sticky" by users, making them unlikely to be canceled even during economic downturns. • GLP-1 and Weight Loss Strategy: * HIMS has started offering branded Novo Nordisk GLP-1 prescriptions. * The analyst notes that HIMS never offered compounded versions of Eli Lilly’s drugs (Tirzepatide), potentially leaving the door open for a future partnership with Eli Lilly (LLY). * Pricing for the Novo pill through Hims is reportedly $30 lower than analyst expectations, increasing its competitive edge. • Peptide Manufacturing Advantage: * HIMS recently acquired a cutting-edge peptide manufacturing facility (formerly part of CS Bio) in Silicon Valley. * This acquisition positions HIMS to be a leader in the peptide space, especially as the FDA potentially removes restrictions on various peptides.

Takeaways

• Ignore Short-Term Volatility: The current price action is attributed to "broken market" dynamics and macro uncertainty rather than company-specific failures. • Long-Term Thesis: The analyst views HIMS as a core holding for the 2030s, focusing on its transition from a simple telehealth provider to a sophisticated personalized medicine and manufacturing platform. • Competitive Moat: The combination of an exceptional UI/UX app, clear pricing, and the recent move into physical manufacturing of peptides creates a significant barrier to entry for smaller players. • Regulatory Resilience: While the FDA is cracking down on "copycat" compounders, the analyst believes HIMS is better protected due to its high-level documentation and its shift toward branded partnerships.

Eli Lilly (LLY) & Novo Nordisk (NVO)

• Mentioned in the context of the weight loss drug market and their relationship with distribution platforms like HIMS. • Wegovy (Novo Nordisk) recently released studies claiming higher effectiveness than Lilly pills, though the analyst views this as standard pharmaceutical competition.

Takeaways

• Partnership Potential: There is speculation that HIMS could become a major distributor for these pharmaceutical giants because HIMS has avoided "knocking off" certain patented drugs, maintaining a cleaner relationship with manufacturers like Lilly.

Investment Themes & Sectors

Telehealth & Direct-to-Consumer (DTC) Healthcare

• The sector is evolving from simple consultations to integrated platforms that include labs, diagnostics, and proprietary manufacturing. • Insight: As insurance premiums rise across the U.S., consumers may opt out of traditional insurance and move toward "cash-pay" platforms like HIMS for routine and maintenance health needs.

Peptides

• A major emerging theme. Peptides (including GLP-1s) are naturally occurring, but drug companies patent modified versions. • Insight: The analyst is highly bullish on the "peptide movement," suggesting that companies with their own manufacturing facilities (like HIMS) will have a first-mover advantage as the FDA approves more of these substances.

Macro Environment ("The Broken Market")

• The analyst characterizes the 2020s as a "lost decade" where stocks trade on political news and liquidity flows rather than fundamentals. • Insight: For investors with a medium-term outlook, the strategy suggested is to ignore "casino-like" daily price movements and focus on businesses that provide essential, recession-proof services.